Bicycle Therapeutics plc (BCYC)Healthcare | Biotechnology | Cambridge, United Kingdom | NasdaqGS
3.63 USD
-0.17
(-4.474%) ⇩
(Oct. 13, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | Oct. 10, 2026, 8:13 a.m. EDT
The investment case here is severely compromised by deteriorating fundamentals and a toxic operational environment. The company is trading below its cash pile, yet it is burning through capital aggressively with negative free cash flow and a massive operating loss. Revenue has collapsed by nearly 80%, and the business is hemorrhaging money with gross margins in the negative territory. This is not a value opportunity; it is a distressed biotech firm where the core product engine has stalled. The operational picture is equally grim. Recent headlines confirm a strategic pivot involving layoffs and a refocusing of the pipeline, while insiders are actively selling shares and granting options to executives at prices that suggest they see limited upside. The stock has already punished investors hard, dropping significantly over the last few months, and the recent price action shows no sign of a sustainable recovery, hovering near multi-month lows. While the balance sheet technically holds enough cash to survive for a while, the path to profitability is obscured by the lack of revenue and the high burn rate. The market is correctly pricing this as a speculative gamble on a future pipeline success rather than a functioning business. With no dividend to provide income and a high beta amplifying volatility, this is a high-risk instrument unsuitable for capital preservation. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.049811 |
| AutoETS | 0.051575 |
| AutoARIMA | 0.051590 |
| MSTL | 0.051917 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 47% |
| H-stat | 1.54 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.214 |
| Excess Kurtosis | -1.19 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 2.873 |
| Revenue per Share | 0.88 |
| Market Cap | 253,414,752 |
| Forward P/E | -1.63 |
| Beta | 1.68 |
| Website | https://www.bicycletherapeutics.com |
As of Oct. 10, 2026, 8:13 a.m. EDT: Speculators are heavily positioned for downside protection, with massive open interest in out-of-the-money puts (strikes 3.0 and 3.5) compared to negligible call volume. While there is some call activity at the 5.0 strike, the overwhelming weight of options flow is defensive, suggesting a belief that the stock will struggle to recover from current lows.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.5189873 |
| Address1 | Portway Building |
| Address2 | Blocks A & B Granta Park Great Abington |
| All Time High | 62.075 |
| All Time Low | 3.33 |
| Ask | 4.68 |
| Ask Size | 2 |
| Average Daily Volume10 Day | 541,880 |
| Average Daily Volume3 Month | 378,420 |
| Average Volume | 378,420 |
| Average Volume10Days | 541,880 |
| Beta | 1.682 |
| Bid | 2.74 |
| Bid Size | 2 |
| Book Value | 7.309 |
| City | Cambridge |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United Kingdom |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 3.63 |
| Current Ratio | 12.076 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 3.88 |
| Day Low | 3.63 |
| Debt To Equity | 2.873 |
| Display Name | Bicycle Therapeutics |
| Dividend Yield | 0.0 |
| Earnings Timestamp | 1,785,414,600 |
| Earnings Timestamp End | 1,793,277,000 |
| Earnings Timestamp Start | 1,793,277,000 |
| Ebitda | -200,812,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | 1.202 |
| Enterprise To Revenue | -3.943 |
| Enterprise Value | -241,316,880 |
| Eps Current Year | -2.45375 |
| Eps Forward | -2.22375 |
| Eps Trailing Twelve Months | -2.73 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 3.9459 |
| Fifty Day Average Change | -0.31589985 |
| Fifty Day Average Change Percent | -0.08005775 |
| Fifty Two Week Change Percent | -51.89873 |
| Fifty Two Week High | 9.08 |
| Fifty Two Week High Change | -5.45 |
| Fifty Two Week High Change Percent | -0.60022026 |
| Fifty Two Week Low | 3.33 |
| Fifty Two Week Low Change | 0.3000002 |
| Fifty Two Week Low Change Percent | 0.09009015 |
| Fifty Two Week Range | 3.33 - 9.08 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,558,618,200,000 |
| Float Shares | 7,759,410 |
| Forward Eps | -2.22375 |
| Forward P E | -1.6323777 |
| Free Cashflow | -99,822,128 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 288 |
| Fullday Change | 0.0 |
| Fullday Change Percent | 0.0 |
| Fullday Price | 3.63 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | -2.0889301 |
| Gross Profits | -127,853,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.044060003 |
| Held Percent Institutions | 0.71902 |
| Implied Shares Outstanding | 69,811,225 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. The company's products pipeline include zelenectide pevedotin, a bicycle toxin conjugate (BTC), which is in phase II clinical trials for the treatment of high nectin-4 expressing tumors; nuzefatide pevedotin (EphA2), a BTC that is in phase I/II clinical trials to treat Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle tumor-targeted immune cell agonist molecule, which is in phase I/II targeting nectin-4 and agonizing CD137; and BT1702, a theranostic BRC molecule targeting MT1-MMP for which IND-enabling activities are ongoing. In addition, it develops Novel CNS targets, which is in preclinical trial targeting CNS disease; Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease; and programs that are in preclinical trial targeting radiopharmaceutical. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Ionis Pharmaceuticals, Inc.; Genentech, Inc; and AstraZeneca AB. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom. |
| Market | us_market |
| Market Cap | 253,414,752 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_72510621 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -190,412,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 251,974,335 |
| Number Of Analyst Opinions | 6 |
| Open | 3.81 |
| Operating Cashflow | -206,050,000 |
| Operating Margins | -86.739265 |
| Phone | 44 1223 261 503 |
| Previous Close | 3.8 |
| Price Eps Current Year | -1.4793684 |
| Price Hint | 4 |
| Price To Book | 0.49664798 |
| Price To Sales Trailing12 Months | 4.1404257 |
| Profit Margins | 0.0 |
| Quick Ratio | 11.703 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.17 |
| Regular Market Change Percent | -4.47368 |
| Regular Market Day High | 3.88 |
| Regular Market Day Low | 3.63 |
| Regular Market Day Range | 3.63 - 3.88 |
| Regular Market Open | 3.81 |
| Regular Market Previous Close | 3.8 |
| Regular Market Price | 3.63 |
| Regular Market Time | 1,791,921,601 |
| Regular Market Volume | 457,019 |
| Return On Assets | -0.17906 |
| Return On Equity | -0.32296002 |
| Revenue Growth | -0.785 |
| Revenue Per Share | 0.88 |
| Sand P52 Week Change | 0.17502642 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 50,373,281 |
| Shares Percent Shares Out | 0.047199998 |
| Shares Short | 3,302,888 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 3,281,399 |
| Short Name | Bicycle Therapeutics plc |
| Short Percent Of Float | 0.0846 |
| Short Ratio | 7.64 |
| Source Interval | 15 |
| Symbol | BCYC |
| Target High Price | 14.0 |
| Target Low Price | 5.0 |
| Target Mean Price | 9.5 |
| Target Median Price | 9.5 |
| Total Cash | 510,052,000 |
| Total Cash Per Share | 7.287 |
| Total Debt | 14,661,000 |
| Total Revenue | 61,205,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -2.73 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 4.780575 |
| Two Hundred Day Average Change | -1.1505747 |
| Two Hundred Day Average Change Percent | -0.24067706 |
| Type Disp | Equity |
| Volume | 457,019 |
| Website | https://www.bicycletherapeutics.com |
| Zip | CB21 6GS |